# Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA

> **NCT07400341** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 66 (estimated)

## Conditions studied

- MDS (Myelodysplastic Syndrome)
- Aplastic Anemia (AA)

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Recombinant Human Thrombopoietin

## Key facts

- **NCT ID:** NCT07400341
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400341, "Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07400341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*